The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

Tatham, Kate C; Shankar-Hari, Manu; Arabi, Yaseen M

Tatham, Kate C; Shankar-Hari, Manu; Arabi, Yaseen M.

Tatham KC; Royal Marsden NHS Foundation Trust, 203 Fulham Road, London, SW3 6JJ, UK.
Shankar-Hari M; Department of Surgery and Cancer, Imperial College London, London, England, UK.
Arabi YM; Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, ICU Support Offices, 1st Floor, East Wing, London, SE1 7EH, UK. manu.shankar-hari@kcl.ac.uk.

Intensive Care Med ; 47(11): 1315-1318, 2021 11.

Article in English | MEDLINE | ID: covidwho-1453698

Subject(s)

COVID-19; Antibodies, Monoclonal, Humanized; Humans; Receptors, Interleukin; Respiration, Artificial; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Randomized controlled trials Limits: Humans Language: English Journal: Intensive Care Med Year: 2021 Document Type: Article Affiliation country: S00134-021-06540-w

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google